SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for cancer treatment. The company's website is www.sellaslifesciences.com.

The company's pipeline centers on two primary product candidates. Galinpepimut-S, or GPS, is a peptide immunotherapy targeting the Wilms tumor 1 antigen, which is overexpressed in approximately 20 cancer types including acute myeloid leukemia, multiple myeloma, malignant pleural mesothelioma, and various solid tumors. GPS utilizes a heteroclitic peptide technology platform designed to enhance immune response against WT1-expressing cancer cells through activation of both CD4 and CD8 T-cells. The company's lead program involves an ongoing Phase 3 randomized clinical trial called REGAL, evaluating GPS as monotherapy in AML patients who have achieved second complete remission following second-line therapy. GPS has received Orphan Drug Designations and Fast Track designations from the FDA for AML, mesothelioma, and multiple myeloma, as well as Rare Pediatric Disease designation for pediatric AML.

The company's second product candidate, SLS009 (tambiciclib), is a highly selective small molecule CDK9 inhibitor licensed from GenFleet Therapeutics. SLS009 is being developed for hematologic and solid malignancies, with clinical development focused on relapsed or refractory AML and lymphomas. The company completed a Phase 1 trial and is conducting Phase 2 studies in combination with venetoclax and azacitidine. SLS009 has also received Orphan Drug Product designations and Fast Track designations for AML and peripheral T-cell lymphoma, as well as Rare Pediatric Disease designations for pediatric acute lymphoblastic leukemia and pediatric AML.

SELLAS in-licensed GPS from Memorial Sloan Kettering Cancer Center and maintains exclusive rights outside Greater China through a separate agreement with 3D Medicines for development in mainland China, Hong Kong, Macau, and Taiwan. The company has no manufacturing, sales, marketing, or distribution capabilities and relies on contract research organizations and contract manufacturing organizations to conduct clinical trials and manufacture product candidates. As a clinical-stage biopharmaceutical company, SELLAS currently has no product revenues and continues to incur substantial operating losses while advancing its development programs.